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Introduction
Epithelial ovarian cancer (EOC) is the most lethal
gynecologic cancer among women. An estimated 600
new cases are diagnosed in Taiwan annually, and approx-
imately 350 women will die from the disease [1]. The
high mortality rate of this disease may be partly
explained by the difficulty in early diagnosis and lack of
a reliable screen test. Current management for advanced
EOC is cytoreductive surgery followed by combination
chemotherapy, usually a platinum-based (mostly car-
boplatin plus paclitaxel) regimen. With the combina-
tion of surgery and chemotherapy, the median survival
of patients with advanced disease is around 44 months
[2]. Despite this progress in primary treatment of EOC
in the past decade, most patients will relapse, highlight-
ing the need for effective and well-tolerated regimens
for recurrent disease. To date, there is no curative treat-
ment for these patients. The main goals of second-line
treatments are to control symptoms and maintain
quality of life, and if possible, to improve progression-
free survival (PFS) and overall survival (OS).
It has become clear over the last decade that the
likelihood of response to chemotherapy at the time of
recurrence is directly proportional to the time between
completion of first-line chemotherapy and the confirma-
tion of recurrent disease. The treatment-free or platinum-
free interval has been shown to strongly predict the
chance of response to a second-line chemotherapy. Based
on the data of Markman and Hoskins [3], patients with
recurrent disease are divided into two subgroups: those
with platinum-refractory/resistant disease and those with
platinum-sensitive disease. Platinum-refractory/resistant
Taiwan J Obstet Gynecol • December 2007 • Vol 46 • No 4 379
MANAGEMENT OF RELAPSED/REFRACTORY
EPITHELIAL OVARIAN CANCER: CURRENT
STANDARDS AND NOVEL APPROACHES
Hao Lin, Chan-Chao Changchien*
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chang Gung Memorial 
Hospital–Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
SUMMARY
Approximately 60% to 70% of epithelial ovarian cancers are diagnosed at an advanced stage. Treatment of
advanced disease involves cytoreductive surgery followed by systemic treatment with paclitaxel and platinum.
Overall response rates are high, ranging from 70–80%; however, 70–80% of responders will relapse and require
further systemic chemotherapy. Patients who experience disease relapse with platinum-free interval of less 
than 6 months are considered as platinum-refractory/resistant individuals. In this clinical setting, agents with 
non-cross-resistance to first-line therapy and favorable toxicity profiles are usually chosen. In the management
of relapsed patients with platinum-free interval over 6 months, the generally accepted recommendation is
retreatment with a platinum plus paclitaxel combination. In general, treatment of recurrent disease is palliative
and is initiated with the goals of controlling disease-related symptoms, limiting treatment-related toxicity, main-
taining or improving quality of life, delaying time to progression, and prolonging survival. A number of currently
available and novel investigating agents in recurrent epithelial ovarian cancer will be reviewed in this context.
[Taiwan J Obstet Gynecol 2007;46(4):379–388]
Key Word: relapsed ovarian cancer
*Correspondence to: Dr Chan-Chao Changchien, Division of Gyne-
cologic Oncology, Department of Obstetrics and Gynecology,
Chang Gung Memorial Hospital–Kaohsiung Medical Center, 123,
Ta Pei Road, Niao Sung Hsiang, Kaohsiung, Taiwan.
E-mail: chanchao@adm.cgmh.org.tw
Accepted: June 14, 2007
■ REVIEW ARTICLE ■
disease is characterized by no response to prior platinum
chemotherapy or progression within the first 6 months
after the end of primary therapy. Secondary non-cross-
resistant chemotherapies or biologic therapies should
be considered. The median PFS in this group of patients
is around 22 weeks and the median OS about 40 weeks.
Platinum-sensitive disease is characterized by a response
to prior platinum chemotherapy (at least partial re-
sponse) and a progression-free interval of at least 
6 months. This group shows the best responses to re-
treatment with a platinum-containing regimen. In gen-
eral, the longer the platinum-free interval, the greater
the expectation of durable response to retreatment.
The median PFS and OS are around 40 and 60 weeks,
respectively. Therefore, before initiating second-line che-
motherapy, it is important to determine the interval
between the completion of therapy with cisplatin or
carboplatin and the development of recurrent disease.
Timing of Treatment
The most debated question remains the timing of treat-
ment in patients with an asymptomatic increase of the
tumor marker CA125, without detectable lesions on
clinical or radiologic examinations. Although rising
CA125 in asymptomatic patients is highly predictive of
clinical recurrence within 4–6 months [4,5], whether
treatment should be delayed until appearance of symp-
toms or initiated solely on the increase in CA125 level
to prevent symptom occurrence remains controversial.
However, this is being addressed in an on-going ran-
domized trial. The kinetics of the CA125 increase, as
well as the patient’s inclination for treatment, should
help with the decision.
Current Treatment Options for 
Platinum-refractory/resistant EOC
As implied by the name, for patients with platinum-
refractory/resistant disease, the standard of care is non-
platinum chemotherapy or biologic therapy. The main
goals are to alleviate symptoms, maintain quality of life,
delay tumor progression, and prolong survival. Various
agents with moderate activity are available for these
patients. Currently, there are no data supporting a
combination therapy for this group of patients.
Pegylated liposomal doxorubicin
Pegylated liposomal doxorubicin (PLD) is a stealth lipo-
somal form of doxorubicin that differs from conven-
tional doxorubicin in its long plasma half-life, extended
circulation time, and distribution throughout the body.
It has been approved by the United States’ Food and
Drug Administration (FDA) in 2005 for treatment of
relapsed EOC patients. A response rate of 18–25% has
been shown in patients with both platinum- and/or
paclitaxel-refractory/resistant EOC receiving single-agent
PLD at a dose of 50 mg/m2 every 4 weeks in two previ-
ous phase II studies [6,7]. A similar response rate of
23–28% has also been reported in Taiwanese popula-
tions but with a lower dose at 40–45 mg/m2 every 
4 weeks [8,9]. The median PFS and OS were about 
5 months and 12 months, respectively. Only 12% and
20% of patients developed grade 3–4 neutropenia and
palmar-plantar erythrodysesthesia, respectively. Other
grade 3–4 toxicities were very rare. Several advantages
were observed from previous studies of using PLD, such
as fewer dose modifications, less frequent treatment
for low blood counts, and a lower total cost per patient.
In addition, PLD improved cardiac safety when com-
pared with free doxorubicin. Based on the survival and
side-effect advantages and the once-monthly dosing
schedule, PLD is considered to be the first choice for non-
platinum chemotherapy for relapsed ovarian cancer.
Topotecan
Topotecan, a topoisomerase I inhibitor, has also been
approved by the FDA for the treatment of relapsed EOC.
It has been extensively evaluated as a single agent in
patients with platinum-refractory/resistant EOC. In
phase II studies of topotecan that was administered
intravenously on days 1 to 5 at a dose of 1.5 mg/m2/
day of a 21-day cycle, objective response rates ranging
from 6% to 17.8% have been reported [10–12]. The
major toxicities were leukocytopenia and neutropenia,
which were grade 3–4 in almost 60–70% of patients. In
a phase III study comparing topotecan and PLD in the
treatment of platinum-refractory/resistant EOC [13],
the response rates (6.4% vs. 12.3%), PFS (13.6 weeks vs.
9.1 weeks), and OS (41.3 weeks vs. 35.6 weeks) did not
differ significantly. However, grade 3–4 neutropenia was
observed in almost 80% of patients in the topotecan
arm but only 10% in the PLD arm. Owing to the sub-
stantial myelosuppression following administration,
alternative dosing schedules such as once weekly have
been evaluated in an attempt to minimize toxicity while
maintaining antitumor activity. In recent phase II studies
using topotecan 4 mg/m2 on days 1, 8, 15 of a 28-day
cycle in treating relapsed EOC, objective response rates
of 14–23% were reported, while only 10–30% of patients
experienced grade 3–4 neutropenia [14,15]. Based on
these data, weekly topotecan may be an appropriate
treatment option for patients with recurrent ovarian can-
cer, especially heavily pretreated patients who might
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require dosing schedules with improved tolerability. 
A randomized phase II trial directly evaluating topote-
can administered daily for 5 days every 3 weeks versus
weekly topotecan with one week off is now ongoing
(Gynecologic Oncology Group-146Q trial).
Paclitaxel
For more than 15 years, platinum-based combination
chemotherapy has been the cornerstone of frontline
chemotherapy for ovarian cancer. With the develop-
ment of paclitaxel in the 1990s, platinum plus pacli-
taxel has become the standard treatment all over the
world. Fortunately, the mechanisms of acquired drug
resistance are different between paclitaxel and plat-
inum, and not all patients with platinum-resistant dis-
ease are resistant to paclitaxel, even if paclitaxel was
included in their frontline treatment program. Further-
more, the spectrum of toxicity varies widely depending
on the schedule of drug administration, which raises a
possibility that alternative schedules may increase the
likelihood of response in patients with refractory/
resistant disease. In a phase I study, paclitaxel adminis-
tered intravenously as a 1-hour infusion every week at
a dose of 80 mg/m2 did not result in cumulative
myelosuppression while maintaining activity [16]. Since
then, weekly administration at a dose of 80 mg/m2 has
been extensively investigated by several groups with
reports suggesting that 10–20% of patients will achieve
an objective response [17–22]. Serious adverse events
were relatively uncommon with grade 3–4 neurotoxicity
at around 5–15%, while grade 3–4 hematologic toxici-
ties were rarely encountered. Based on these results,
weekly paclitaxel is a reasonable treatment option for
patients with refractory/resistant ovarian cancer, bal-
ancing efficacy, toxicity, and quality of life benefits.
Oral etoposide
The “standard” 3-day intravenous etoposide regimen,
originally developed for lung cancer treatment, has lim-
ited activity in ovarian cancer. However, several studies
reported that a prolonged 21-day low-dose oral etopo-
side regimen (50 mg/m2/day) resulted in a 25% objec-
tive response rate in the second-line setting in patients
with ovarian cancer [23,24]. The major toxicity of oral
etoposide is bone marrow suppression, with grade 3–4
neutropenia occurring in about 45% of patients. Oral
etoposide has the clear advantage of convenient home
administration, requiring, however, weekly evaluation
of blood counts.
Gemcitabine
Gemcitabine, approved by the FDA for treatment of
pancreatic cancer, has been demonstrated to be an
active second-line agent in relapsed ovarian cancer.
Gemcitabine is generally administered on a weekly
schedule for 3 consecutive weeks, followed by a 1-week
treatment break using a dose of 800 to 1,100 mg/m2/
week as a 30-minute infusion. Several phase II trials
have revealed a 15% to 20% objective response rate in
this clinical setting [25–28]. Gemcitabine has been
reported to be well tolerated, with major side effects
being grade 3–4 neutropenia in 30–50% of patients.
Docetaxel
Docetaxel is an inhibitor of microtubule depolymeriza-
tion and has demonstrated activity in both platinum-
and paclitaxel-resistant EOC but with significant
hematologic toxicity. In phase II studies of docetaxel
that was administered intravenously as 1-hour infusion
at a dose of 75–100 mg/m2 every 3 weeks, objective
response rates ranging from 10% to 22% have been
reported [29,30]. The principal adverse effect of grade
3–4 neutropenia occurred in 50–75% of patients. Several
investigators have evaluated that a lower dose regimen
(30 or 40 mg/m2) administered weekly might result in
a similar response rate with reduced toxicity. The results
were promising with response rates at 7–19% and tox-
icity being grade 3 neutropenia in only 4% of patients
[31,32].
Novel Therapeutic Approaches for
Platinum-refractory/resistant EOC
Bevacizumab (Avastin)
Vascular endothelial growth factor overexpression in
ovarian cancer cells is thought to be an important fac-
tor in tumor angiogenesis and biologic aggressiveness.
Bevacizumab is a humanized recombinant monoclonal
antibody that blocks cancer cells from secreting vascu-
lar endothelial growth factor and is hence called an
anti-angiogenic agent. Bevacizumab has been approved
by the FDA for patients with colorectal cancer and
metastatic breast cancer. Several prospective phase II
trials have also reported significant activity in platinum-
refractory/resistant ovarian cancer. In those reports,
bevacizumab was administered intravenously at a dose
of 15 mg/kg every 3 weeks, and an objective response
rate of 16–18% was observed [33,34]. Common toxic-
ities associated with bevacizumab included hyperten-
sion, proteinuria, and wound healing complications
and did not differ from other phase II and III studies
performed in non-gynecologic cancers. Recently, bowel
perforations associated with bevacizumab have gained
significant attention, because they seem to be more
common in ovarian cancer than other solid tumors. 
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In a review article, the overall risk of bowel perforations
from bevacizumab therapy was 5.4% [35]. Although
the risk is not so high, it is life-threatening. The pa-
thophysiologic mechanism by which bowel perfora-
tions occur is unknown, but it is thought that when
bevacizumab destroys the cancer cells in the bowel
serosa, it leaves perforations in the bowel. Further stud-
ies are necessary to continue to assess the safety of
bevacizumab.
Trabectedin (ET-743, Yondelis)
Trabectedin, a novel marine-derived chemotherapeutic
agent, was discovered in the colonial tunicate Ecteinascidia
turbinata and is now produced synthetically. Trabectedin
has a unique mechanism of action. It binds to the minor
groove of the DNA and interferes with the cell division
and genetic transcription processes and the DNA repair
machinery. The recommended dosing schedules of tra-
bectedin varies, ranging from 1.2–1.65 mg/m2 given as a
1-, 3-, 24- or 72-hour intravenous infusion every 3 weeks,
with the most prevalent dose-limiting toxicities being
hematologic [36–38]. In a phase II trial with patients
with platinum-refractory/resistant EOC, the objective
response rate was 7% (43% in platinum-sensitive disease)
at a dose of 1.3 mg/m2 given as a 3-hour infusion every
3 weeks. The predominant toxicities were grade 3–4
neutropenia and thrombocytopenia in 41% and 8% of
the patients, respectively [39]. Additional studies to
establish empirical dosing guidelines as a single agent or
in combination regimens may be necessary to improve
the efficacy and safety of the drug.
Epothilones
The epothilones are a novel class of non-taxane 
microtubule-stabilizing agents obtained from the fer-
mentation of the cellulose-degrading myxobacteria,
Sorangium cellulosum. Similar to paclitaxel and other tax-
anes, the epothilones block cells in mitosis, resulting in
cell death [40]. Preclinical studies have shown that the
epothilones are more potent than the taxanes and are
active in some taxane-resistant models [41]. The major
components of the fermentation process are epothilones
A and B, with epothilones C and D found in smaller
amounts. Preclinical studies have shown that epothilone
B (patupilone) is the most active form, exhibiting sig-
nificantly higher antitumor activity than paclitaxel and
docetaxel [42]. In a phase I/II trial with patients with
relapsed/refractory ovarian cancer, patupilone at a
dose of 10.5 mg/m2 administered intravenously over
10–20 minutes every 3 weeks was safe and well toler-
ated with an objective response rate of 16%. The prin-
cipal adverse effect of grade 3–4 diarrhea and fatigue
occurred in 17% and 14% of the patients, respectively
[43]. A randomized, parallel-group, multicenter phase III
trial of patupilone (10.5 mg/m2 every 3 weeks) versus
PLD (50 mg/m2 every 4 weeks) in platinum-refractory/
resistant EOC is now ongoing [44]. The main objectives
are to access tumor response, PFS, and time to pro-
gression compared with conventional PLD. Results will
be reported in the near future.
TLK286 (Telcyta): a cytotoxic prodrug
TLK286 was designed to exploit the overexpression of
glutathione S-transferase P1-1 (GST P1-1), an enzyme
overexpressed in many human cancer cells. High levels
of GST P1-1 are associated with a poor prognosis and
resistance to certain chemotherapeutics. Preclinical
studies suggest that the activation of TLK286 occurs
when GST P1-1 splits TLK286 into two active fragments:
a glutathione analog fragment and an active cytotoxic
fragment [45]. The cytotoxic fragment reacts with
important cell components, including RNA, DNA and
proteins, leading to cell death (Figure 1). The glu-
tathione analog fragment of TLK286 may remain bound
to GST P1-1, which may limit the ability of GST P1-1
to inactivate other cancer drugs, thus reversing drug
sensitivity. The results of preclinical studies provide a
rationale for its use in the clinical management of 
platinum-resistant ovarian cancer [46]. In a phase II trial
with patients with platinum-refractory/resistant EOC,
an objective response rate of 15% (50% with stable dis-
ease) at a dose of 1,000 mg/m2 given as a 30-minute
infusion every 3 weeks was observed [47]. There were no
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cytotoxic fragment region is released 
Figure 1. TLK286 is activated by the enzyme glutathione 
S-transferase (GST) P1-1. Once activated, the cytotoxic 
fragment is released, inducing apoptosis.
grade 4 toxicities. Grade 3 toxicities were infrequent,
and no cumulative toxicities were seen in this popula-
tion. Later, phase I/II studies regarding outcomes in
platinum-refractory patients with TLK286 in combina-
tion with carboplatin (TLK286 500 mg/m2, carboplatin
at an area under curve [AUC] 5) or PLD (TLK286
960 mg/m2, PLD 50 mg/m2) were presented [48,49].
The combination showed enhanced efficacy with a
response rate of 46% to 56% being observed. Grade 3
neutropenia was reported in 62% of patients receiving
the TLK286–carboplatin combination. Because of the
promising results, the ASSIST-Ovarian (ASsessment of
Survival In Solid Tumors) phase III clinical trials are
currently being conducted to compare TLK286 (either
alone or in combination with carboplatin or PLD) with
drugs already approved for the treatment of recurrent
ovarian cancer (PLD and topotecan) [50]. The results
will be reported in the near future.
Phenoxodiol
Phenoxodiol, an isoflavone analog, belongs to a new
class of anticancer drugs known as multiple signal trans-
duction regulators. The drug regulates signal pathways
in cancer cells. It works selectively on cancer cells and
induces cancer cell death through inhibition of anti-
apoptotic proteins, including X-linked inhibitor of apo-
ptosis protein (XIAP) [51]. XIAP was shown to be
overexpressed in chemo-resistant cells, and phenoxo-
diol may serve as a chemosensitizer by interfering with
XIAP activity [52,53]. A phase I study showed that
phenoxodiol at a dose of 30 mg/kg/day given by intra-
venous infusion continuously for 7 days on 14-day
cycles was well tolerated [54]. Phenoxodiol is now
being tested for women with refractory/resistant ovar-
ian cancer as a chemosensitizer (OVATURE trial). This
is a multicenter, randomized, double-blind, phase III
efficacy study comparing phenoxodiol in combination
with carboplatin versus carboplatin with placebo. The
study has started since October 2006 and is expected
to recruit 470 patients [55].
Others targeted agents
Other novel targeted agents being investigated in the
treatment of ovarian cancer include anti-CA125 anti-
body (oregovomab), anti-epidermal growth factor recep-
tor (EGFR) antibody (cetuximab), EGFR tyrosine kinase
inhibitor (gefitinib), anti-HER2/neu antibody (per-
tuzumab), and proteasome inhibitor (bortezomib). All
these agents show clinical activity and present a different
safety profile from that of conventional chemothera-
peutic agents. Combination strategies with platinum/
taxane-based therapy are being evaluated for some of
these inhibitors/antibodies in phase II/III trials. The
response rate to treatment with various single agents
in patients with EOC in refractory/resistant relapse are
summarized in Table 1.
Current Treatment Options for 
Platinum-sensitive EOC
Patients in this clinical setting are frequently considered
candidates for retreatment with regimens, similar to
those previously received in the frontline therapy, includ-
ing cisplatin, carboplatin or paclitaxel. Current studies
have shown that platinum combination chemotherapy
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Table 1. Response rate to treatment with single agent in patients with platinum-refractory/resistant relapse
Agent References Principal grade 3–4 toxicity ORR (%)
PLD 6, 7, 8, 9, 13 Neutropenia, 12%; PPE, 20% 18–28
Topotecan (q3w) 10, 11, 12, 13 Neutropenia, 70–80% 6–18
Topotecan (qw) 14, 15 Neutropenia, 10–30% 14–23
Paclitaxel (qw) 17, 18, 19, 20, 21, 22 Neuropathy, 5–15% 10–20
Oral etoposide 23, 24 Neutropenia, 45% 25
Gemcitabine 25, 26, 27, 28 Neutropenia, 30–50% 15–20
Docetaxel (q3w) 29, 30 Neutropenia, 50–75% 10–22
Docetaxel (qw) 31, 32 Neutropenia, 4% (grade 3) 7–19
Bevacizumab 33, 34, 35 Bowel perforation, 5.4% 16–18
Trabectedin 39 Neutropenia, 41%; thrombocytopenia, 8% 7
Epothilones (patupilone) 43 Diarrhea, 17%; fatigue, 14% 16
TLK286 47 Rare 15
TLK286 + carboplatin 48 Neutropenia, 62%; thrombocytopenia, 37% 63
TLK286 + PLD 49 Neutropenia, 12%; fatigue, 6% 46
Phenoxodiol 54 NA NA
ORR = overall response rate; PLD = peg ylated liposomal doxorubicin; PPE = palmar/planter erythrodysesthesia; q3w = every 3 weeks; qw = every week; NA = no
phase II trial available.
achieves superior outcomes with regard to survival or
quality of life compared with the use of single agents.
In selected patients, secondary cytoreductive surgery
before initiation of chemotherapy may have some role
in survival benefit.
Secondary cytoreductive surgery
Until today, only few publications have focused on selec-
tion criteria for secondary cytoreductive surgery in recur-
rent ovarian cancer. Based on available data, secondary
cytoreductive surgery is best considered only for those
patients who have all of the following characteristics:
(1) disease-free interval of at least over 12 to 18 months,
(2) response to frontline chemotherapy, (3) younger
age, (4) good performance status, and (5) potentially
can be rendered free of all gross residual disease [56,57].
However, it is difficult to preoperatively predict whether
it will be possible to achieve complete tumor resection.
In a retrospective analysis, factors associated with suc-
cessful surgery include no residual disease after initial
surgery, good performance status, absence of ascites,
and no evidence of peritoneal carcinomatosis. A com-
plete resection was shown to be possible in 81% of
patients when all these criteria were present [58].
Platinum plus paclitaxel
Results of the International Collaborative Ovarian Neo-
plasm 4 (ICON4)/AGO-OVAR 2.2) trial suggest that
combination treatment with a platinum–paclitaxel dou-
blet shows a survival benefit over single-agent platinum
in patients with relapsed platinum-sensitive ovarian
cancer [59]. This randomized trial compared a mini-
mum of six cycles of single-agent platinum chemother-
apy versus platinum–paclitaxel doublet in 802 patients
with relapsed ovarian cancer. A treatment-free interval
of more than 6 months was required. In this setting,
platinum–paclitaxel doublet therapy yielded a response
rate (66%) that was superior to single-agent platinum
(54%). At a median follow-up of 42 months, the hazard
ratio for PFS was 0.76 (12 vs. 9 months; p = 0.0004),
favoring platinum–paclitaxel doublet. The hazard ratio
for OS was 0.82 (p = 0.0023), corresponding to an
absolute difference in 2-year survival of 7% (57% vs.
50%) and median survival of 5 months (29 vs. 24
months), favoring the platinum–paclitaxel doublet.
However, the improved survival was accompanied by
increased grade 3–4 neurologic toxicity (20% vs. 1%)
and alopecia (86% vs. 25%).
Carboplatin plus gemcitabine
In view of the high incidence of neurotoxicity and alope-
cia which should be avoided in patients in relapse, the
Gynecologic Cancer InterGroup (GCIG) trial AGO-OVAR
2.5 randomized 356 patients with platinum-sensitive
disease to carboplatin–gemcitabine doublet (carbo-
platin: AUC 4, day 1; gemcitabine: 1,000 mg/m2, days 1
and 8) versus single-agent carboplatin (AUC 5) every 
3 weeks [60]. A significantly higher overall response rate
was observed in the carboplatin–gemcitabine doublet
group (47.2% vs. 30.9%; p = 0.0016). Also, the combi-
nation regimen produced a significantly longer PFS
compared with the single-agent carboplatin control
arm (8.6 vs. 5.8 months) with a hazard ratio of 0.72
(95% confidence interval, 0.50–0.90 months; p=0.003).
The trial was not powered for OS. Alopecia and neuro-
toxicity rates were low in both arms, but grade 3–4
hematologic toxicities were significantly more common
with combination therapy (78.3% vs. 24.7%). Based on
the results of the above two randomized trials, there 
is enough evidence to conclude that platinum-based
doublet chemotherapy is superior to single-agent car-
boplatin in patients with recurrent platinum-sensitive
ovarian cancer; however, there is still a need for car-
boplatin-based combinations, which may offer the
best outcome while minimizing toxicity and preserving
quality of life.
Carboplatin plus PLD
A more recent phase II study conducted by Groupe des
Investigateurs Nationaux pour l’Etude des Cancers de
l’Ovaire (GINECO) also has shown activity for other
combination regimens, including the combination of
carboplatin (AUC 5) and PLD (30 mg/m2) adminis-
tered every 4 weeks [61]. The overall response rate was
63%, with 38% of patients demonstrating complete
response. Although the population enrolled in this
large phase II trial of 105 patients was slightly different
from those enrolled in ICON4/AGO-OVAR 2.2 and
GCIG/AGO-OVAR 2.5, PFS and OS were similar for
carboplatin plus PLD and platinum plus paclitaxel.
Hematologic and non-hematologic toxicities were low,
with less than 15% of patients experiencing grade 2
alopecia, grade 2 or 3 infection, mucositis, hand–foot
syndrome or neuropathy. The data suggest that com-
bination therapy with carboplatin and PLD may be a
feasible alternative to platinum–paclitaxel doublet ther-
apy in relapsed ovarian cancer patients with platinum-
sensitive disease. These encouraging results have
prompted the GCIG to launch a randomized trial
comparing the efficacy and tolerability of carboplatin
(AUC 5) combined with either PLD (30 mg/m2) or
paclitaxel (175 mg/m2) in patients with ovarian cancer
in late relapse (CALYPSO trial, AGO-OVAR 2.9). The
study is ongoing and is expected to recruit 864 patients.
The results of the above three major trials are summa-
rized in Table 2.
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Non-platinum single agent
As discussed previously, current treatment options for
patients with platinum-sensitive ovarian cancer include
retreatment with a platinum doublet combination.
Although a survival benefit has been demonstrated
with combined therapy, 7–10% of patients are unable
to tolerate retreatment because of neuropathy, myelo-
suppression or hypersensitivity [62]. In these patients,
non-platinum agent such as PLD should be the treat-
ment of choice, as it has clearly shown to have a sur-
vival advantage compared with topotecan in a phase III
clinical trial [13]. In this phase III clinical trial compar-
ing PLD with topotecan in 220 women with platinum-
sensitive relapsed EOC, the response rates in both
arms were similar (28% vs. 29%), long-term follow-up
showed that PLD significantly prolonged OS com-
pared with topotecan (107.9 vs. 70.1 weeks; p = 0.017).
Although the response rate was somewhat lower than
that of platinum doublet regimens, it is difficult to
compare results across studies owing to differences in
patient populations.
There are some probable potential benefits of using
non-platinum (especially PLD) single agents in patients
with platinum-sensitive disease. First, it offers compara-
ble response rates and long-term stable disease. Second,
it avoids the cumulative side effects associated with the
continued use of platinum and thus improves quality
of life. Third, it may increase the subsequent response to
platinum reintroduction by expanding the platinum-free
interval and thus offers the best chance for long-term
survival.
Ongoing trials (PLD with/without 
trabectedin, ET743-OVA-301)
This is a global, randomized controlled study comparing
the combination of PLD (30 mg/m2, 90-minute infusion)
followed by trabectedin (1.1 mg/m2, 3-hour infusion,
every 3 weeks) with PLD (50 mg/m2, 90-minute infusion,
every 4 weeks) in patients with relapsed EOC. PLD and
trabectedin have different mechanisms of action with
different cellular targets and non-overlapping toxicity.
From the preliminary PLD and trabectedin combination
phase I study data in a variety of tumor types [63], the
combination regimen provided an improved efficacy
with an acceptable safety profile. Therefore, the ratio-
nale for the study is to determine whether the combi-
nation is superior over either agent alone. This ongoing
trial proposed to enroll 650 patients over 2 years (till
July 2007) from approximately 120 sites (six sites from
Taiwan) all over the world. Additional 2–3 years may
be required to observe the results.
Future Directions
A number of novel agents are being investigated to
identify strategies more effective than conventional
chemotherapy for the treatment of advanced EOC in
both the frontline and recurrent settings. However, the
measurement of the efficacy of these agents might need
to be reassessed, since many of these agents might have
cytostatic effects; and thus, the criteria applied to tra-
ditional cytotoxic compounds might be less applicable
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Table 2. Comparison of efficacies and toxicities of platinum doublet regimens for patients with platinum-sensitive relapse
Platinum/paclitaxel Carboplatin/gemcitabine Carboplatin/PLD
(ICON4/AGO-OVAR 2.2 [59]) (GCIG/AGO-OVAR 2.5 [60]) (GINECO [61])
Number of patients 392 175 105
Platinum-free interval (%)
6–12 months 24 40 47
> 12 months 76 60 53
Efficacy
Overall response rate (%) 66 47 63
Median PFS (mo) 12 8.6 9.4
Median OS (mo) 26 18 32
Adverse events (%)*
Neutropenia, grade 3–4 29† 70.3 51
Neurotoxicity, ≥ grade 2 20 6.3 7
Alopecia, ≥ grade 2 86 14.3 12
Mucositis, ≥ grade 2 7 – 12
PPE, ≥ grade 2 0 0 11
*Based on National Cancer Institute Common Toxicity Criteria version 2.0 and later; †hematologic toxic effect leading to treatment modification or interruption
reported. PLD = pegylated liposomal doxorubicin; PFS = progressive-free survival; OS = overall survival; PPE = palmar/planter erythrodysesthesia.
in determining the clinical benefit. Another great chal-
lenge is identifying the most relevant and clinically sig-
nificant targets for ovarian cancer, since many of these
cancers carry multiple molecular defects.
Conclusion
In defining the optimal therapeutic strategy for recurrent
ovarian cancer, there is no widely accepted standard for
platinum-refractory/resistant disease. In the absence
of demonstrated superiority of combination regimen
over single-agent regimen, the therapy in this clinical
setting is sequential single-agent treatment and should
be based on side-effect profile and other quality-of-life
issues. The combination of paclitaxel with carboplatin,
on the other hand, is considered as the standard
chemotherapy for the treatment of relapsing patients
with platinum-free interval over 6 months. Regimens
substituting new drugs, such as gemcitabine or PLD,
to paclitaxel in association with carboplatin may offer
platinum-based combinations with better toxicity pro-
file and quality of life. Selected platinum-sensitive
patients with localized disease may also be suitable
candidates for secondary cytoreductive surgery prior
to the initiation of chemotherapy (Figure 2). In addi-
tion, the availability of several new drugs with activity
in ovarian cancer has allowed a better control of recur-
rences with survival prolongation. However, even these
strategies may not prove sufficiently effective, and con-
tinued study of molecular and genetic targeted thera-
pies through vectors and monoclonal antibodies may
ultimately be the only breakthrough. We hope that the
next decade will yield significant progress in the treat-
ment of this catastrophic disease.
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